R&D Trends

Amgen, Cytokinetics expand collaboration

Thursday, June 13, 2013 01:30 PM

Amgen and Cytokinetics, a clinical-stage biopharmaceutical company, have expanded their strategic collaboration to include Japan. In 2006, Cytokinetics and Amgen entered into a collaboration to discover, develop and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for potential applications in the treatment of heart failure. Omecamtiv mecarbil is the most advanced drug candidate in this collaboration.  

More... »

Evotec, Harvard collaborate on development of antibacterials

Wednesday, June 12, 2013 02:22 PM

Evotec, a drug discovery alliance and development partnership company, is collaborating with Harvard University, aiming to discover and develop novel antibacterial agents based on a target family involved in bacterial cell wall biosynthesis.

More... »

HHS partners with GSK for new antibiotics

Wednesday, June 12, 2013 02:19 PM

GlaxoSmithKline and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), are collaborating to support the development of several antibiotics to fight antibiotic resistance and bioterrorism.

More... »

Achaogen awarded $60M contract

Wednesday, June 12, 2013 02:16 PM

Achaogen, a biopharmaceutical company focused on discovering, developing and commercializing treatments for serious infections caused by multi-drug resistant gram-negative bacteria, has been awarded a $60 million contract option from the Biomedical Advanced Research and Development Authority (BARDA). The option supports the conduct of a global phase III study to evaluate the efficacy and safety of plazomicin in treating patients with gram-negative bacterial infections due to CRE.

More... »

TauRx Therapeutics, Toronto Memory Program announce phase III trials

Wednesday, June 12, 2013 02:14 PM

Neurodegenerative disease specialist TauRx Therapeutics and Toronto Memory Program have joined in the Canadian launch of the phase III clinical trials of TauRx Therapeutics' LMTX, the company's investigational treatment aimed at slowing or halting the progression of mild to moderate Alzheimer's disease.

More... »

AbbVie and Galapagos extend GLPG0634 collaboration

Monday, June 10, 2013 11:39 AM

Galapagos, which specialized in novel modes-of-action, and AbbVie have extended their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a phase II program in Crohn's, designed to facilitate rapid progression into phase III.  Upon successful completion of the study, expected in the second quarter of 2015, AbbVie will pay Galapagos $50 million. 

More... »

R&D nonprofit to collaborate on use of predictive analytics

Monday, June 10, 2013 11:34 AM

The Gordon and Betty Moore Foundation, which focuses on environmental conservation, patient care and scientific research, awarded a grant to the Parkland Center for Clinical Innovation (PCCI), a nonprofit R&D corporation. PCCI will collaborate with international informaticists, health services researchers, statisticians and legal and ethical experts who will identify how the use of real-time healthcare predictive analytics can make a positive impact on patient outcomes and costs. The experts will initially meet in Washington D.C.

More... »

AbbVie, Alvine collaborate on investigational oral therapy

Monday, June 10, 2013 11:28 AM

AbbVie and Alvine Pharmaceuticals, a developer of celiac disease therapeutics, have entered a global collaboration to develop a novel oral treatment for patients with celiac disease, currently in phase II development.

More... »

Bill Gates, Tenaya Capital invest in ResearchGate

Friday, June 7, 2013 01:58 PM

ResearchGate, a professional network for scientists, has a new investment from Bill Gates and Tenaya Capital with participation from Dragoneer Investment Group, Thrive Capital and the company's existing investors Benchmark and Founders Fund.

More... »

CytomX, Pfizer collaborate to develop and commercialize in oncology

Friday, June 7, 2013 01:54 PM

CytomX Therapeutics, a biotechnology company developing a new generation of targeted antibody therapeutics, has entered into a global collaboration with Pfizer to develop and commercialize multiple Probody-Drug Conjugates (PDCs).

More... »